Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
Enter Symbol
Company
Overview
Research Notes
Company Profile
Competitors
Community
Wiki
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Related News
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Shares Outstanding:
426M
Market Cap:
$8.99B
Avg Volume:
5461958
P/E Ratio:
9.930
PEG Ratio:
0.760
Split:
On 10/9/2003 myl split by factor of 1.500
Trade now with
1m
3m
6m
1y
2y
Opinion and Analysis
Mylan (MYL) Launches Generic Viramune To Treat HIV, AIDS
May 23, 2012 12:43 PM |
MYL
Mylan's (MYL) Generic Version Of Blood Thinner Plavix Gets FDA Approval
May 17, 2012 02:50 PM |
MYL
,
SNY
Mylan (MYL) PT Lifted To $26 By RBC Capital On Positive Developments, 'Outperform' Maintained
May 16, 2012 04:29 PM |
MYL
Goldman Sachs (GS): M&A Remains Dominant Theme In Healthcare This Year
May 11, 2012 10:01 AM |
AGN
,
ALXN
,
CERN
,
CPSI
,
CVH
,
EW
Mylan (MYL): Generic Lipitor Launched In U.K., France
May 11, 2012 08:39 AM |
MYL
,
PFE
,
WPI
More Articles on MYL..
Market News
Women who are CEOs of Fortune 500 companies
Oct 26, 2011 11:42 AM |
ADM
,
AVP
,
CPB
,
GCI
,
HPQ
,
KEY
Dey Pharma receives patent reexamination certificates for Perforomist patents
Oct 21, 2011 05:40 AM |
MYL
Energy sector fuels jobs surge in Western Pennsylvania
Oct 01, 2011 03:58 AM |
CNX
,
MYL
,
RRC
USPTO to reissue Perforomist patents to Dey Pharma
Aug 04, 2011 07:44 AM |
MYL
Home-grown jugaad set for patent cover
Jul 04, 2011 12:47 PM |
MYL
More News on MYL..
Press Releases
Merck and Mylan Look to Benefit From Plan to Speed up FDA Reviews
May 24, 2012 08:20 AM |
MRK
,
MYL
Moody's Upgrades Mylan
May 23, 2012 01:34 PM |
MYL
Mylan Launches Generic Version of Viramune? Tablets
May 23, 2012 11:42 AM |
MYL
More Press Releases on MYL..
SEC Filings
Form 4 MYLAN INC. For: May 15 Filed by: COURY ROBERT J (10K)
May 15, 2012 05:20 PM
Form 4 MYLAN INC. For: May 04 Filed by: TODD C B (10K)
May 07, 2012 05:09 PM
Form 4 MYLAN INC. For: May 04 Filed by: VANDERVEEN RANDALL L (10K)
May 07, 2012 05:05 PM
More SEC Filings on MYL..
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
MYL
Compare to S&P
YTD
-1.91 %
-10.11 %
4 Weeks
-4.23 %
-3.35 %
12 Weeks
-8.32 %
-9.51 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
-1.89 %
EPS Growth in Last Year:
18.18 %
Sales Growth in Last Quarter:
4.00 %
Sales Growth in Last Quarter:
9.90 %
More...
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##